
Sign up to save your podcasts
Or


This episode was released in February 2021, and is being re-shared to offer the research behind the popular weight loss drugs Ozempic and Wegovy. Northwestern's Robert Kushner, MD, discusses the drug semaglutide, typically prescribed for treatment of Type 2 diabetes and the results of the phase 3 clinical trial as a treatment for obesity with very promising results. The study was published in the New England Journal of Medicine, and in 2022, Kushner was awarded the prestigious Herbert Pardes Clinical Research Excellence Award from the Clinical Research Forum.
By Northwestern University Feinberg School of Medicine4.9
2424 ratings
This episode was released in February 2021, and is being re-shared to offer the research behind the popular weight loss drugs Ozempic and Wegovy. Northwestern's Robert Kushner, MD, discusses the drug semaglutide, typically prescribed for treatment of Type 2 diabetes and the results of the phase 3 clinical trial as a treatment for obesity with very promising results. The study was published in the New England Journal of Medicine, and in 2022, Kushner was awarded the prestigious Herbert Pardes Clinical Research Excellence Award from the Clinical Research Forum.

91,086 Listeners

21,934 Listeners

43,552 Listeners

91 Listeners

6,471 Listeners

113,159 Listeners

5 Listeners

56,945 Listeners

0 Listeners

10,331 Listeners

33 Listeners

3,048 Listeners

8,220 Listeners

29,360 Listeners

1,586 Listeners

4,351 Listeners

7 Listeners

630 Listeners

14,049 Listeners